EI
TBPH icon

Ellevest Inc’s Theravance Biopharma TBPH Stock Holding History

Ellevest Inc’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-42
Closed -$456 – 1471
2023
Q1 		$456 Hold
42
– – ﹤0.01% 1687
2022
Q4 		$471 Hold
42
– – ﹤0.01% 1629
2022
Q3 		$0 Buy
42
+13
+45% +$122 ﹤0.01% 1856
2022
Q2 		$0 Hold
29
– – ﹤0.01% 1681
2022
Q1 		$0 Sell
29
-8
-22% -$78 ﹤0.01% 1627
2021
Q4 		$0 Buy
37
+18
+95% +$157 ﹤0.01% 1643
2021
Q3 		$0 Buy
19
+10
+111% +$112 ﹤0.01% 1576
2021
Q2 		$0 Hold
9
– – ﹤0.01% 1415
2021
Q1 		$0 Hold
9
– – ﹤0.01% 1356
2020
Q4 		$0 Buy
+9
New +$162 ﹤0.01% 1350

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellevest Inc's TBPH Position: Q2 2023 in Review

Ellevest Inc sold out of Theravance Biopharma (TBPH) in Q2 2023, closing a stake of 42 shares — an estimated $456 sold.

Ellevest Inc first reported a position in TBPH in Q4 2020 and held it in 10 quarters. The position peaked at $471 in Q4 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

  • Ellevest Inc reported no remaining Theravance Biopharma position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 42 Theravance Biopharma shares in Q2 2023, an estimated $456.
  • Ellevest Inc first reported a position in Theravance Biopharma in Q4 2020 and held it in 10 quarters.
  • Ellevest Inc's Theravance Biopharma position peaked at $471 in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.